Physician profile
Gurpreet S Multani
NPI 1417117979
$7,691.32
in general payments reported to CMS, 2019-2025
58 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,703 · 2020: $1,767 · 2021: $823 · 2022: $25.76 · 2023: $27.93 · 2024: $2,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,345 · Food and Beverage: $27.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,345.00 |
| Food and Beverage | $27.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,537.98 | 2019-2024 | |
| Amgen INC. | $737.59 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $333.46 | 2019-2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $289.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $284.44 | 2019-2021 | |
| Janssen Biotech, INC. | $209.26 | 2019-2021 | |
| Incyte Corporation | $198.61 | 2019-2020 | |
| Lilly USA, LLC | $184.82 | 2019-2020 | |
| Genentech USA, INC. | $174.73 | 2019-2020 | |
| Astellas Pharma US INC | $172.73 | 2019-2021 | |
| Genzyme Corporation | $146.21 | 2019-2020 | |
| Eisai INC. | $143.98 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.98 | 2019-2021 | |
| Pfizer INC. | $139.77 | 2019-2020 | |
| Foundation Medicine, INC. | $130.91 | 2019-2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurpreet Multani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.